Carregant...
4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia
BACKGROUND: Alirocumab and evolocumab (PCSK9-Inhibitors), are new drugs incorporated into the therapeutic arsenal for the treatment of hypercholesterolaemia, having shown effectiveness and safety in the performed clinical trials. PURPOSE: To assess the effectiveness and safety of PCSK9-Inhibitors, t...
Guardat en:
| Publicat a: | Eur J Hosp Pharm |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Group
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535333/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.125 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|